

Supplementary Figure 1: Traffic Light Plot of RoB 2.0 Assessment for Individual Randomized Controlled Trials


Supplementary Figure 2: Summary Plot of RoB 2.0 Assessment for Included Randomized Controlled Trials

Supplementary Figure 3: Funnel plots comparing outcomes between SCB and PCB in ISR patients: (a) Target Lesion Revascularization, (b) Stent thrombosis, (c) Major Adverse Cardiovascular Events, (d) All-Cause Mortality, (e) Cardiac Mortality, (f) Myocardial Infarction


Supplementary Table 1: Quality Assessment of the observational study through New Castle Ottawa Scale

Supplementary Table 2: GRADE Assessment of the Outcomes

Supplementary Figure 1: Traffic Light Plot of RoB 2.0 Assessment for Individual Randomized Controlled Trials




Supplementary Figure 2: Summary Plot of RoB 2.0 Assessment for Included Randomized Controlled Trials




Supplementary Figure 3: Funnel plots comparing outcomes between SCB and PCB in ISR patients: (a) Target Lesion Revascularization, (b) Stent thrombosis, (c) Major Adverse Cardiovascular Events, (d) All-Cause Mortality, (e) Cardiac Mortality, (f) Myocardial Infarction


a) Target Lesion Revascularization




b) Stent Thrombosis




c) MACE




d) All-Cause Mortality



e) Cardiac Mortality



f) Myocardial Infarction



Supplementary Table 1: Quality Assessment of the observational study through New Castle Ottawa Scale

Study	Selection				Comparability	Outcome			Total
	1	2	3	4	1	1	2	3	
Ray et al. 2025	★	★	★	★	★★	★	★	★	9/9

Supplementary Table 2: GRADE Assessment of the Outcomes

Name of Outcome	No. of Studies	Study Design	Risk of Bias	Inconsistency	Imprecision	Indirectness	Effect Size (RR + CI)	Certainty of Evidence
Target Lesion Revascularization	4	RCT + Observational	Serious	Not serious (I ² =0%, P=0.75, no heterogeneity)	Serious (wide CI: 0.72–2.06)	Not serious	RR=1.22 (95% CI: 0.72–2.06)	Low
Stent Thrombosis	3	RCT	Serious	Not serious (I ² =0%, P=0.61, no heterogeneity)	Serious (wide CI: 0.57–1.78)	Not serious	RR=1.01 (95% CI: 0.57–1.78)	Low
Major Adverse Cardiovascular Events	3	RCT	Serious	Not serious (I ² =0%, P=0.80, no heterogeneity)	Serious (wide CI: 0.70–1.90)	Not serious	RR=1.15 (95% CI: 0.70–1.90)	Low
All-Cause Mortality	3	RCT	Serious	Not serious (I ² =0%, P=0.69, no heterogeneity)	Serious (wide CI: 0.11–4.06)	Not serious	RR=0.67 (95% CI: 0.11–4.06)	Low
Cardiac Mortality	2	RCT	Serious	Not serious (I ² =0%, P=0.77, no heterogeneity)	Serious (wide CI: 0.16–10.28)	Not serious	RR=1.28 (95% CI: 0.16–10.28)	Low
Myocardial Infarction	2	RCT	Serious	Not serious (I ² =0%, P=0.35, no heterogeneity)	Serious (wide CI: 0.10–9.44)	Not serious	RR=0.99 (95% CI: 0.10–9.44)	Low